Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism

Published:January 27, 2017DOI:


      • Testosterone replacement therapy can be delivered intramuscularly, nasally, buccally, and topically.
      • Transdermal testosterone is effective at regulating testosterone levels.
      • Depo-Testosterone promotes patient compliance, is safe, and is affordable.
      • Nurse practitioners should initiate testosterone replacement with Depo-Testosterone.


      Testosterone replacement therapy (TRT) is 1 treatment option for men with hypogonadism. When TRT is prescribed, effectiveness, patient compliance, cost, and potential side effects should be considered and used to develop an individualized treatment plan. Depo-Testosterone (Pfizer Inc, New York, NY, USA) is the most cost-efficient TRT option and is only administered every 2 weeks, which may improve patient compliance, although the dose interval can be adjusted to once per week. Androderm is the most efficacious TRT medication, with up to 92% of patients reaching normal testosterone levels. Testim (Endo Pharmaceuticals Inc, Malvern, PA, USA) and Vogelxo (Upsher-Smith Laboratories Inc, Maple Grove, MN, USA) have the fewest reported side effects. We recommend Depo-Testosterone as a first-line treatment option.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal


      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Osterberg E.C.
        • Bernie A.M.
        • Ramasamy R.
        Risks of testosterone replacement therapy in men.
        Indian J Urol. 2014; 30: 2-7
        • Bhattacharya R.K.
        • Bhattacharya S.B.
        Late-onset hypogonadism and testosterone replacement in older men.
        Clin Geriatr Med. 2015; 31: 631-644
        • Oskui P.M.
        • French W.J.
        • Herring M.J.
        • Mayeda G.S.
        • Burstein S.
        • Kloner R.A.
        Testosterone and the cardiovascular system: a comprehensive review of the clinical literature.
        J Am Heart Assoc. 2013; 2: 1-22
        • Arver S.
        • Dobs A.S.
        • Meikle A.W.
        • et al.
        Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
        Clin Endocrinol. 1997; 47: 727-737
        • Mattern C.
        • Hoffmann C.
        • Morley J.E.
        • Badiu C.
        Testosterone supplementation for hypogonadal men by the nasal route.
        Aging Male. 2008; 11: 171-178
        • Ross R.J.M.
        • Jabbar A.
        • Jones T.H.
        • et al.
        Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men.
        Eur J Endocrinol. 2004; 150: 57-63
        • Wang C.
        • Cunningham G.
        • Dobs A.
        • et al.
        Long-term testosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
        J Clin Endocrinol Metab. 2004; 89: 2085-2098
        • Wang C.
        • Swerdloff R.
        • Kipnes M.
        • et al.
        New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
        J Clin Endocrinol Metab. 2004; 89: 3821-3829
        • Dobs A.S.
        • Matsumoto A.M.
        • Wang C.
        • Kipnes M.S.
        Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
        Curr Med Res Opin. 2004; 20: 729-738
        • Grober E.D.
        • Khera M.
        • Soni S.D.
        • Espinoza M.G.
        • Lipshultz L.I.
        Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
        Int J Impot Res. 2008; 20: 213-217
        • Korbonits M.
        • Slawik M.
        • Cullen D.
        • et al.
        A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males.
        J Clin Endocrinol Metab. 2004; 89: 2039-2043
        • Mazer N.
        • Bell D.
        • Wu J.
        • Fischer J.
        • Cosgrove M.
        • Eilers B.
        Comparison of the steady-state pharmacokinetics, metabolism and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
        J Sex Med. 2005; 2: 213-226
        • Steidle C.
        • Schwartz S.
        • Jacoby K.
        • et al.
        AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
        J Clin Endocrinol Metab. 2003; 88: 2673-2681
        • Bhasin S.
        • Cunningham G.R.
        • Hayes F.J.
        • et al.
        Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline.
        J Clin Endocrinol Metab. 2010; 95: 2536-2559
        • Hassan J.
        • Barkin J.
        Testosterone deficiency syndrome: Benefits, risks, and realities associated with testosterone replacement therapy.
        Can J Urol. 2016; 23: 20-30
      1. Stop paying too much for your prescriptions. 2016. Accessed December 19, 2016.

      2. Snyder PJ. Testosterone treatment of male hypogonadism. In: Matsumoto M, Martin KA, eds. UpToDate. 2016. Accessed May 12, 2016.

        • Epocrates
        Epocrates Premium Version. Epocrates, Inc, San Mateo, CA2016
      3. Food and Drug Administration. [email protected] : FDA approved drug products. 2016. Accessed May 12, 2016.

      4. American Society of Health-System Pharmacists. Testosterone enanthate injection. 2014. Accessed January 22, 2017.

      5. Drug price information. 2016. Accessed January 22, 2017.

        • Claxton A.J.
        • Cramer J.
        • Pierce C.A.
        Systematic review of the associations between dose regimens and medication compliance.
        Clin Ther. 2001; 23: 1296-1310


      Karlen E. Luthy, DNP, FNP, is an associate professor at Brigham Young University in Provo, UT, and can be reached at [email protected].


      Chris Williams, MS, FNP, is a Nurse Practitioner at Premier Family Medical in Lehi, UT.


      Donna S. Freeborn, is an associate professor at Brigham Young University.


      Aaron Cook, PharmD, is a pharmacist at Walgreens Pharmacy in Payson, UT.